Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
First-in-class clinical trial of IL-33 blockade shows inhibition of neutrophil migration into human skin and modulates atopic dermatitis symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, this improvement lasted for up to 140 days after the single dose.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a proof-of-concept study with a single application of the anti-IL-33 antibody etokimab (ANB020) in 12 patients with moderate or severe AD, 33% of patients reached the primary end point EASI75 and 83% reached EASI50 (ref.68).”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [68]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Etokimab inhibited direct, as well as CXCR1-dependent, neutrophil migration in vitro.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP
Soumelis, V., Reche, P. A., Kanzler, H., Yuan, W., Edward, G., Homey, B., Gilliet, M., Ho, S., Antonenko, S., Lauerma, A., et al. (2002) · Nature Immunology · doi:10.1038/ni805 · Cited by 2,183
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301668 · Cited by 1,547
Self-citationA role for IL-25 and IL-33–driven type-2 innate lymphoid cells in atopic dermatitis
Salimi, M., Barlow, J. L., Saunders, S. P., Xue, L., Gutowska-Owsiak, D., Wang, X., Huang, L.-C., Johnson, D., Scanlon, S. T., McKenzie, A. N. J., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130351 · Cited by 979 · cited 1×
“The IL-33/ST2 pathway contributes to inflammation associated with disorders including atopic dermatitis (AD) (7), asthma (8), inflammatory bowel disease (9), and arthritis (10, 11).”
BackgroundSelf-citationγ-Secretase-mediated proteolysis in cell-surface-receptor signalling
Fortini, M. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm910 · Cited by 824
TSLP Elicits IL-33–Independent Innate Lymphoid Cell Responses to Promote Skin Inflammation
Kim, B. S., Siracusa, M. C., Saenz, S. A., Noti, M., Monticelli, L. A., Sonnenberg, G. F., Hepworth, M. R., Van Voorhees, A. S., Comeau, M. R., & Artis, D. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005374 · Cited by 731 · cited 1×
“In murine models, either IL-33 or TSLP alone is sufficient to promote the development of AD-like inflammation (39).”
BackgroundSilverberg, J. I., & Hanifin, J. M. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.08.031 · Cited by 604
IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G
Lefrançais, E., Roga, S., Gautier, V., Gonzalez-de-Peredo, A., Monsarrat, B., Girard, J.-P., & Cayrol, C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115884109 · Cited by 594 · cited 1×
“Furthermore, IL-33 can be cleaved into active forms by neutrophil elastase and cathepsin G (21), implicating an inflammatory cycle.”
BackgroundThaçi, D., Simpson, E. L., Beck, L. A., Bieber, T., Blauvelt, A., Papp, K., Soong, W., Worm, M., Szepietowski, J. C., Sofen, H., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00388-8 · Cited by 572
Soluble ST2 Blocks Interleukin-33 Signaling in Allergic Airway Inflammation
Hayakawa, H., Hayakawa, M., Kume, A., & Tominaga, S.-I. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704916200 · Cited by 546 · cited 1×
“The soluble IL-33 decoy receptor soluble ST2 (sST2) has been used in treating allergic diseases in model systems (27).”
Cited by
Items 101–200 of 259
Immune Modulation in Asthma: Current Concepts and Future Strategies
Lommatzsch, M. (2020) · Respiration · doi:10.1159/000506651 · Cited by 27
DeVore, S. B., Gonzalez, T., Sherenian, M. G., Herr, A. B., & Hershey, G. K. K. (2020) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2020.08.025 · Cited by 25
Ungar, B., Manson, M., Kim, M., Gour, D. S., Temboonnark, P., Metukuru, R., da Rosa, J. C., Estrada, Y. D., Gay-Mimbrera, J., Gómez‐Arias, P. J., et al. (2025) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2025.01.082 · Cited by 28
Minaga, K., Watanabe, T., Hara, A., Yoshikawa, T., Kamata, K., & Kudo, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.713779 · Cited by 24
“Therefore, an anti-ST2 Ab or etokimab (62) targeting IL-33-mediated signaling pathways might be a unique therapeutic option for patients with AIP and IgG4-RD.”
BackgroundQuirce, S., Cosío, B. G., España, A., Blanco, R., Mullol, J., Santander, C., & del Pozo, V. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1192284 · Cited by 27
Novel Analgesics with Peripheral Targets
Ciotu, C. I., & Fischer, M. J. M. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00937-z · Cited by 23
Kosloski, M. P., Guttman‐Yassky, E., Cork, M. J., Worm, M., Nahm, D., Zhu, X., Ruddy, M. K., Harel, S., Kamal, M. A., Goulaouic, H., et al. (2024) · Clinical and Translational Science · doi:10.1111/cts.13874 · Cited by 23
“25,26 However, it was unclear to what extent outcomes in that phase IIb study were specific to etokimab and the design of that study or generalizable to the anti- IL-33 mechanism of action.”
Borgia, F., Custurone, P., Peterle, L., Pioggia, G., & Gangemi, S. (2021) · Biomolecules · doi:10.3390/biom11121843 · Cited by 22
Bergmann, C., Poli, A., Agache, I. O., Bianchini, R., Bax, H. J., Castells, M., Crescioli, S., Dombrowicz, D., Ferastraoaru, D. E., Fiebiger, E., et al. (2022) · Allergy · doi:10.1111/all.15255 · Cited by 21
Laquer, V. T., Parra, V., Lacour, J. ‐., Takahashi, H., Knorr, J., Okragly, A. J., James, D. E., Sims, J. T., Chang, C.-Y., Chao, J., et al. (2022) · British Journal of Dermatology · doi:10.1111/bjd.21631 · Cited by 20
Reese, A. E., Moliner, F. D., Mendive‐Tapia, L., Benson, S., Kuru, E., Bridge, T., Richards, J., Rittichier, J., Kitamura, T., Sachdeva, A., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c01125 · Cited by 20
Gunji, Y., Matsumura, T., Karasawa, T., Komada, T., Baatarjav, C., Komori, S., Aizawa, H., Mizushina, Y., Tsuda, H., Miyake, K., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02630-6 · Cited by 22
“…of Etokimab, a monoclonal antibody targeting IL-33, signi fi cant reductions were observed in peripheral blood eosinophil and neutrophil in fi ltration in the skin of AD patients [13], suggesting that IL-33 contributes to both Th2-mediated eosinophilic in fi ltration and neutrophilic in fl ammation.”
A Novel Plant Leaf Patch Absorbed With IL-33 Antibody Decreases Venous Neointimal hyperplasia
Xie, B., Bai, X., Sun, P., Zhang, L., Wei, S., & Bai, H. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.742285 · Cited by 19
Kim, S., Ko, E., Choi, H. G., Kim, D., Luchi, M., Khor, B., & Kim, S. (2022) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2022.100185 · Cited by 20
Alopecia areata exhibits cutaneous and systemic OX 40 activation across atopic backgrounds
Kim, M., DUCA, E. D., Dahabreh, D., Lozano‐Ojalvo, D., Carroll, B. E., Manson, M., Bose, S. N., Gour, D. S., NandyMazumdar, M., Liu, Y., et al. (2024) · Allergy · doi:10.1111/all.16268 · Cited by 19
Wu, K., Wang, X., Keeler, S. P., Gerovac, B. J., Agapov, E. V., Byers, D. E., Gilfillan, S., Colonna, M., Zhang, Y., & Holtzman, M. J. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000181 · Cited by 21
Nakahara, T., Izuhara, K., Onozuka, D., Nunomura, S., Tamagawa‐Mineoka, R., Masuda, K., Ichiyama, S., Saeki, H., Kabata, Y., Abe, R., et al. (2020) · Medicine · doi:10.1097/md.0000000000022043 · Cited by 21
“Other lesional and blood markers including eosinophils, lactate dehydrogenase (LDH),([14]) total immunoglobulin E (IgE),([15]) soluble IL-2 receptor,([16]) CCL27,([14]) IL-13,([17]) IL-22,([9]) IL24,([18,19]) IL-25,([20]) IL-31,([21,22]) IL-33,([23]) thymic stromal lymphopoietin (TSLP),([24]) periostin,([9,25]) and sq…”
BackgroundIL-31/33 Axis in Atopic Dermatitis
Łacwik, J., Kraik, K., Laska, J., Tota, M., Sędek, Ł., & Gomułka, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010162 · Cited by 20
“These results indicate the important role of IL-33 in the pathogenesis of AD and the therapeutic potential of its blockade [117].”
Neural Regulation of Innate Immunity in Inflammatory Skin Diseases
Huang, X., Li, F., & Wang, F. (2023) · Pharmaceuticals · doi:10.3390/ph16020246 · Cited by 20
“Lebrikizumab mAb AD [110]; NCT04146363; NCT04178967; NCT04392154; NCT04250350; NCT04250337 IL-33 Etokimab mAb AD [111]; NCT03533751 TSLP Tezepelumab mAb AD [112]; NCT02525094; NCT03809663”
Bonzano, L., Borgia, F., Casella, R., Miniello, A., Nettis, E., & Gangemi, S. (2023) · Biomolecules · doi:10.3390/biom13071100 · Cited by 20
Biologics for atopic diseases: Indication, side effect management, and new developments
Jappe, U., Beckert, H., Bergmann, K., Gülşen, A., Klimek, L., Philipp, S., Pickert, J., Rauber, M. M., Renz, H. E., Taube, C., et al. (2021) · Allergologie · doi:10.5414/alx02197e · Cited by 25
Qi, H.-J., & Li, L. (2021) · BioMed Research International · doi:10.1155/2021/5528372 · Cited by 19
A New Era with the Development of Cytokine-Based Therapy for Pruritus
Shibuya, R., Takimoto‐Ito, R., Kambe, N., & Kabashima, K. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.09.023 · Cited by 20
Dellon, E. S., Simon, D., & Wechsler, M. E. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.01.043 · Cited by 19
The involvement of keratinocytes in pruritus of chronic inflammatory dermatosis
Lin, S., Liu, X., Jian, J., Ge, W., Zhang, Y., Li, F., Tao, Q., Liu, S., Li, M., & Chen, H. (2024) · Experimental Dermatology · doi:10.1111/exd.15142 · Cited by 19
“118 However, IL-33 is more pleiotropic, as it not only induces the production of pruritogenic type 2 cytokines like IL-4, IL-13 and IL-31, but also directly activates sensory neurons.”
Honstein, T., & Werfel, T. (2020) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000652 · Cited by 18
Eosinophil Lineage-Committed Progenitors as a Therapeutic Target for Asthma
Salter, B., Ju, X., & Sehmi, R. (2021) · Cells · doi:10.3390/cells10020412 · Cited by 18
Biologics in food allergy: up-to-date
Passanisi, S., Caminiti, L., Zirilli, G., Lombardo, F., Crisafulli, G., Aversa, T., & Pajno, G. B. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1904888 · Cited by 17
Targeted therapy for immune mediated skin diseases. What should a dermatologist know?
López, E., Cabrera, R., & Lecaros, C. (2024) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2023.10.002 · Cited by 17
Anselmo‐Lima, W. T., Tamashiro, E., Romano, F. R., Miyake, M. M., Roithmann, R., Kosugi, E. M., Nakanishi, M., Fornazieri, M. A., Bezerra, T. F. P., de Mello, J. F., et al. (2021) · Brazilian Journal of Otorhinolaryngology · doi:10.1016/j.bjorl.2021.03.003 · Cited by 20
Biological effects of IL-33/ST2 axis on oral diseases: autoimmune diseases and periodontal diseases
Wang, M., Gao, M., & Yi, Z. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110524 · Cited by 18
IL-33 antagonism does not improve chronic atopic dermatitis: What can we learn?
Schuler, C. F., IV, & Gudjonsson, J. E. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.10.009 · Cited by 16
ILC2s: Unraveling the innate immune orchestrators in allergic inflammation
Lu, H.-F., Zhou, Y.-C., Luo, D., Yang, D., Wang, X.-J., Cheng, B., & Zeng, X.-H. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111899 · Cited by 15
Pietka, W., Sundnes, O., Hammarström, C. L., Zucknick, M., Khnykin, D., & Haraldsen, G. (2020) · Scientific Reports · doi:10.1038/s41598-020-63410-z · Cited by 15
Break on Through: The Role of Innate Immunity and Barrier Defence in Atopic Dermatitis and Psoriasis
Hawerkamp, H. C., Fahy, C. M. R., Fallon, P. G., & Schwartz, C. (2022) · Skin Health and Disease · doi:10.1002/ski2.99 · Cited by 16
“Initial studies on the efficacy of etokimab targeting IL‐33 in human moderate‐to‐severe AD showed moderate but sustained improvement in disease severity.(159) While this improvement is associated with reducing innate inflammatory pathways by inhibiting IL‐33, basophils can also activate ILC2s induced by IL‐33, which w…”
BackgroundStrategies targeting IL-33/ST2 axis in the treatment of allergic diseases
Li, W., Liu, M., & Chu, M. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115911 · Cited by 14
Taruselli, M. T., Qayum, A. A., Abebayehu, D., Caslin, H. L., Dailey, J. M., Kotha, A., Burchett, J. R., Kee, S. A., Maldonado, T. D., Ren, B., et al. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2200916 · Cited by 15
Mai, T. T., Lam, T.-P., Pham, L.-H. D., Nguyen, K.-H., Nguyen, Q., Le, M.-T., & Thai, K. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c03057 · Cited by 14
Preventing NLRP3 inflammasome activation: Therapeutic atrategy and challenges in atopic dermatitis
Sun, Y., Zhou, Y., Peng, T., Huang, Y., Lü, H., Ying, X., Kang, M., Jiang, H., Wang, J., Zheng, J., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113696 · Cited by 17
Innate Immune Regulation of Dermatitis
Abreu, D., & Kim, B. (2021) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2021.04.011 · Cited by 15
Casciaro, M., Salvo, E. D., & Gangemi, S. (2021) · Biomolecules · doi:10.3390/biom12010060 · Cited by 14
“Data reported endorse etokimab as an effective biologic in AD, although it is at an initial investigational stage [28].”
BackgroundPruritogenic Mediators and New Antipruritic Drugs in Atopic Dermatitis
Koumaki, D., Gregoriou, S., Evangelou, G., & Krasagakis, K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062091 · Cited by 14
“In a phase 2a clinical trial with a human monoclonal antibody against IL-33, etokimab (ANB020), patients with AD showed significant improvements in 5D itch measures and EASI scores [115].”
BackgroundPotential Aspects of the Use of Cytokines in Atopic Dermatitis
Krupka‐Olek, M., Bożek, A., Aebisher, D., Bartusik‐Aebisher, D., Cieślar, G., & Kawczyk‐Krupka, A. (2024) · Biomedicines · doi:10.3390/biomedicines12040867 · Cited by 13
Tončić, R. J., Jakaša, I., Sun, Y., Hurault, G., Hadžavdić, S. L., Tanaka, R. J., Pavičić, B., Balić, A., Zuzul, K., Petković, M., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17132 · Cited by 14
Rutkowski, D., Scholey, R., Davies, J., Pye, D., Blackhall, F. H., Warren, R. B., Jiménez, F., Griffiths, C. E. M., & Paus, R. (2024) · British Journal of Dermatology · doi:10.1093/bjd/ljae243 · Cited by 12
Biologics in Chronic Rhinosinusitis
Boyd, J. T., & Khanwalkar, A. R. (2024) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2024.07.005 · Cited by 15
T-Cell Mediated Immunity in Merkel Cell Carcinoma
Ouyang, K., Zheng, D. X., & Agak, G. W. (2022) · Cancers · doi:10.3390/cancers14246058 · Cited by 12
Wang, Z., & Tang, N. (2023) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-023-00788-1 · Cited by 14
“Rapid and sustained clinical benefits were observed (Chen et al. 2019 ).”
BackgroundRole of Alarmins in the Pathogenesis of Systemic Sclerosis
Giovannetti, A., Straface, E., Rosato, E., Casciaro, M., Pioggia, G., & Gangemi, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144985 · Cited by 13
Targetable pathogenic mechanisms in nasal polyposis
Schneider, A. L., Schleimer, R. P., & Tan, B. K. (2021) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22787 · Cited by 12
Hołdrowicz, A., & Woźniacka, A. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061754 · Cited by 11
“D Itch Scale [26].”
BackgroundAdvances in understanding the role of interleukins in pulmonary fibrosis (Review)
He, Y., Shen, X., Zhai, K., & Nian, S. (2024) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2024.12775 · Cited by 11
Kupschke, E., & Schenk, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1608338 · Cited by 13
Immunotherapy in Atopic Dermatitis
Li, W., & Man, X. (2022) · Immunotherapy · doi:10.2217/imt-2022-0054 · Cited by 12
Yang, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-64034-z · Cited by 11
Ahn, J., Grinich, E. E., Choi, Y. S., Guttman‐Yassky, E., & Simpson, E. L. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.02.003 · Cited by 11
Repressive Control of Keratinocyte Cytoplasmic Inflammatory Signaling
Carman, L. E., Samulevich, M. L., & Aneskievich, B. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511943 · Cited by 10
Biologic Therapy in Pediatric Chronic Rhinosinusitis: A Systematic Review
Rahavi‐Ezabadi, S., Zhou, S., Lee, S. E., Ference, E. H., Magit, A. E., Leuin, S. C., Mohamed, K., Rezaei, N., & Patel, V. A. (2024) · Otolaryngology · doi:10.1002/ohn.717 · Cited by 10
Dickerson, A., Dellon, E. S., & Aceves, S. S. (2025) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2025.05.016 · Cited by 12
Alarmins/stressorins and immune dysregulation in intractable skin disorders
Yamanishi, K., & Imai, Y. (2021) · Allergology International · doi:10.1016/j.alit.2021.05.005 · Cited by 10
Experimental Drugs with the Potential to Treat Atopic Eczema
Hon, K. E., Chan, V. P. Y., & Leung, A. K. C. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s259299 · Cited by 10
“The role of IL-33 inhibition was investigated in a phase 2a study of etokimab, an IgG1 anti–IL-33 monoclonal antibody, in 12 adult patients with moderate-to-severe AD who received a single intravenous administration of etokimab.(162)”
BackgroundJappe, U., Bergmann, K., Brinkmann, F., Faihs, V., Gülşen, A., Klimek, L., Renz, H., Seurig, S., Taube, C., Traidl, S., et al. (2024) · Allergologie select · doi:10.5414/alx02533e · Cited by 13
Cross-Talk between Neurons and Immune Cells in Pruritus: from Mechanisms To Medicines
Khalil, N. B., Kagan, T., & Yosipovitch, G. (2026) · Current Allergy and Asthma Reports · doi:10.1007/s11882-026-01255-8 · Cited by 9
“A proof-of-concept trial of etokimab (anti–IL-33) in AD also did not demon - strate anti-pruritic effects [ 66].”
An overview of drug discovery efforts for eczema: why is this itch so difficult to scratch?
Hon, K. E., Loo, S. K. F., Leung, A. K. C., Li, J. T. S., & Lee, V. W. Y. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1722639 · Cited by 9
“Etokimab, an IL-33 inhibitor, is another agent under investigation [161].”
BackgroundAtopic dermatitis: a brief review of recent advances in management
Alenazi, S. D. (2023) · Dermatology Reports · doi:10.4081/dr.2023.9678 · Cited by 23
“44 Tezepelumab is an IgG2λ human monoclonal antibody target-Table”
Immunological Targets of Biologic Drugs in Allergic Skin Diseases in Children
Filippo, P. D., Russo, D., Attanasi, M., Pillo, S. D., & Chiarelli, F. (2021) · Biomedicines · doi:10.3390/biomedicines9111615 · Cited by 10
Gastric alarmin release: A warning signal in the development of gastric mucosal diseases
Wu, E., Zhu, J., Ma, Z., Tuo, B., Terai, S., Mizuno, K., Li, T., & Liu, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1008047 · Cited by 10
Clinical trials of antibody drugs in the treatments of atopic dermatitis
Zhou, G., Huang, Y., & Chu, M. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1229539 · Cited by 9
“performed a phase 2a study to evaluate its efficacy and safety (36).”
BackgroundMethodDanto, S. I., Tsamandouras, N., Reddy, P. S., Gilbert, S. A., Mancuso, J. Y., Page, K. M., Peeva, E., Vincent, M. S., & BEEBE, J. S. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2360 · Cited by 9
Franke, K., Li, Z., Bal, G., Zuberbier, T., & Babina, M. (2023) · Cells · doi:10.3390/cells12232700 · Cited by 8
“…an especially close link between IL-33 and atopic dermatitis: while efficacy of anti-IL-33-tageted therapies is still not completely defined, etokimab (a therapeutic anti-IL-33 antibody) showed improvement in skin score and reduced skin neutrophil infiltration after a single administration [104,105].”
BackgroundZhang, Y., Yuan, S., Wu, Y., Nie, W., You, T., Yang, H., & Liu, B. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01659-4 · Cited by 10
Cui, N., Jiang, L., Tang, L., & Tang, H. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112455 · Cited by 8
Rasheed, K., Moens, U. L., Policastro, B., Johnsen, J. I., Koljonen, V., Sihto, H. J., Lui, W., & Sveinbjørnsson, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073702 · Cited by 8
Emerging Systemic Treatment Options in Atopic Dermatitis
Salman, A., & Giménez‐Arnau, A. M. (2024) · Balkan Medical Journal · doi:10.4274/balkanmedj.galenos.2024.2024-5-78 · Cited by 8
A translational approach to improve therapeutics in atopic dermatitis and beyond
Liu, D., Patel, D., Lau, M., Largen, J., Hu, B., He, H., & Guttman‐Yassky, E. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf049 · Cited by 7
Chen, J., Wang, Y., & Wang, X. (2026) · mAbs · doi:10.1080/19420862.2026.2639673 · Cited by 7
Pruritus Characteristics in Severe Atopic Dermatitis in Adult Patients
Jaworek, A., Szafraniec, K., Doniec, Z., Jaworek, M., Wojas‐Pelc, A., & Pokorski, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_548 · Cited by 8
Allergic Contact Dermatitis: Immunopathology and Potential Therapeutic Strategies
Funch, A. B., Geisler, C., & Bonefeld, C. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14207175 · Cited by 7
“Biologics targeting IL-33 (e.g., Etokimab, Tozorakimab) have entered testing in atopic dermatitis, with early proof-of-concept data suggesting reduced disease activity and pruritus, including a significant reduction in neutrophil skin infiltrates [138].”
Riebelmann, J., Kienzle, N., Sauer, B., & Schittek, B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1726557 · Cited by 7
“Consistently, treatment with the anti-IL-33 antibody etokimab in adults with moderate-to-severe AD reduces disease severity and limits in fl ammation by inhibiting neutrophil recruitment (52).”
Okada, S., Sakai, A., Ohnishi, Y., Yasudo, H., Motonaga, T., Fukano, R., Waniishi, T., Sugiyama, M., & Hasegawa, S. (2024) · Circulation Journal · doi:10.1253/circj.cj-24-0295 · Cited by 6
Gusniev, S. A., Polner, S. A., Михалева, Л. М., Ilina, N. I., Yesakova, A. P., Kurbacheva, O. M., Shilovskiy, I. P., & Khaitov, M. R. (2021) · Immunologiya · doi:10.33029/0206-4952-2021-42-1-68-79 · Cited by 6
Biologics for the Treatment of Food Allergies
Brar, K., Lanser, B. J., Schneider, A., & Nowak-Wegrzyn, A. H. (2020) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2020.06.002 · Cited by 8
Luo, Y.-F., Deng, Y., Yang, F., Meiduosiji, Xiong, X., Yuan, Y.-L., & Ao, S.-H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1567817 · Cited by 7
“Etokimab (ANB020), a humanized anti-IL-33 monoclonal antibody, reduced the peripheral eosinophils and skin neutrophil in fi ltration of AD patients in a proof-of-concept clinical trial (169).”
CB2R-cAMP-Epac1 pathway orchestrates epithelial–neural–immune interactions in atopic dermatitis
Hu, X., Luo, Y., Zhang, Y., Liu, K., Wu, L., Hou, J., Zhao, G., Wang, T., Liu, Y., Cheng, H., et al. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.08.021 · Cited by 5
Gao, J., Li, Y., Guan, X., Mohammed, Z., Gomez, G., Hui, Y. Y., Zhao, D., Oskeritzian, C. A., & Huang, H. (2023) · BMC Genomics · doi:10.1186/s12864-023-09702-w · Cited by 6
Interleukin antagonists for atopic dermatitis: a new era of therapy
Tsiogka, A., Paschou, E., Koumaki, D., Vakirlis, E., & Gregoriou, S. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2347294 · Cited by 5
“A proof-of-concept, phase IIA study on twelve patients with AD, who received a single 300 mg dose of etokimab, showed a reduction of EASI and skin neutrophil infiltration and peripheral eosinophils, however, the reduction was not significant [111].”
BackgroundNowicki, R. J., Trzeciak, M., Rudnicka, L., Szepietowski, J. C., Kulus, M., Kupczyk, M., Mastalerz–Migas, A., Peregud-Pogorzelski, J. W., Jahnz‐Różyk, K., Narbutt, J., et al. (2020) · Advances in Dermatology and Allergology · doi:10.5114/ada.2020.100496 · Cited by 6
“These results confirm the role of IL-33 in modulation of the inflammatory cascade in atopic skin and confirm the therapeutic potential of IL-33 in the treatment of AD [47].”
ResultEpithelial-immune interactions govern type 2 immunity at barrier surfaces
Espinoza, A. L., Christopher, T., & Wojno, E. D. T. (2024) · Current Opinion in Immunology · doi:10.1016/j.coi.2024.102501 · Cited by 5
Cazzola, M., Matera, M., Hanania, N., & Rogliani, P. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s552274 · Cited by 4
“Etokimab, another anti-IL-33 mAb, has undergone early-phase evaluation in atopic dermatitis, 115 but there is presently no published evidence supporting its efficacy in asthma, COPD, or ACO.”
Yang, Z., Liu, Y., Xie, Z., & Zheng, M. J. (2026) · Journal of Photochemistry and Photobiology C Photochemistry Reviews · doi:10.1016/j.jphotochemrev.2026.100739 · Cited by 4
Epicutaneous sensitization. what do we know?
Новик, Г. А., Жданова, М. В., & Demidova, A. (2022) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2021-4-180-192 · Cited by 4
Revisiting immunotherapeutic strategies for the management of atopic dermatitis
Siwe, G. T., Fajemisin, E. A., Mugeri, M., Naran, K., & Barth, S. (2024) · doi:10.37349/eaa.2024.00052 · Cited by 4
New Era in Atopic Dermatitis Treatment: Results of Long-Term Dupilumab Administration
Murashkin, N. N., Opryatin, L. A., Epishev, R. V., Materikin, A. I., Ambarchyan, E. T., Ivanov, R. A., Fedorov, D. V., & Kukoleva, D. S. (2021) · Вопросы современной педиатрии · doi:10.15690/vsp.v20i5.2312 · Cited by 4
“В публикациях последних лет продемонстрирована также и роль IL-33 в модулировании каскада воспалительных реакций в коже при АтД [25].”
InfluentialAntibody-based therapeutics for chronic rhinosinusitis with nasal polyps
Shishodia, S., Haloob, N., & Hopkins, C. L. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2370397 · Cited by 4
New views on the diagnosis and treatment of asthma in children
Marushko, Y. V., Абатуров, А. Е., Бекетова, Г. В., Березенко, В. С., Pochynok, T. V., & Churylina, A. V. (2022) · CHILD`S HEALTH · doi:10.22141/2224-0551.17.2.2022.1503 · Cited by 4
Bando, K., Tanaka, Y., Winias, S., Sugawara, S., Mizoguchi, I., & Endo, Y. (2023) · Inflammation Research · doi:10.1007/s00011-023-01699-y · Cited by 5
Knowledge mapping of interleukin-33: a bibliometric study.
Sun, J., Xia, Y., Zhang, D., Yu, Z., Ning, Y., & Tan, Z. (2023) · PubMed Central · Cited by 5
Shi, P., Sun, P., Lou, C., Fang, J., Zhang, L., Xie, B., & Zhang, C. (2024) · Journal of Surgical Research · doi:10.1016/j.jss.2024.11.017 · Cited by 3
Interleukin-33 at the intersection of inflammation and repair
Martinez-Moreno, F., Jerschow, E., Ortega, V., Kita, H., & Chiarella, S. E. (2026) · Frontiers in Allergy · doi:10.3389/falgy.2026.1894127 · Cited by 3
“In atopic dermatitis, a proof-of-concept study with the anti-IL-33 antibody etokimab showed clinical improvement after a single dose, suggesting that IL-33 blockade can alter disease activity in humans (65).”
Nuclear IL-33 as a growth and survival agent within basal cells
Chapman, H. A. (2021) · Journal of Clinical Investigation · doi:10.1172/jci153203 · Cited by 3
Metadata
- Authors
- Chen, Y.-L., Gutowska-Owsiak, D., Hardman, C. S., Westmoreland, M., MacKenzie, T., Cifuentes, L., Waithe, D., Lloyd-Lavery, A., Marquette, A., Londei, M., & Ogg, G.
- Affiliations
- University of Oxford (GB)
- MRC Human Immunology Unit, NIHR Biomedical Research Centre, Radcliffe Department of Medicine, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK.
- AnaptysBio, Inc. (United States) (US)
- Corresponding author
- Ogg, Graham
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2019-10-23
- Volume
- 11
- Issue
- 515
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2979421310
- Cited by
- 250
- References
- 46
- Citations by year
- 2026: 20 · 2025: 25 · 2024: 38 · 2023: 31 · 2022: 48 · 2021: 50 · 2020: 37 · 2019: 1
- FWCI
- 34.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Medical Research Council (MCUU_0008/5)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- atopic dermatitis, neutrophil migration, CXCR1, interleukin-8, eosinophils, skin inflammation, Eczema Area and Severity Index
- MeSH terms
- Interleukin-33, Antibodies, Monoclonal, Cell Movement, Dermatitis, Atopic, Eczema, Humans, Inflammation, Neutrophils, Skin, Interleukin-12, Receptors, Interleukin-8A, Extracellular Fluid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.